Skip to main content

Table 1 Demographics and characteristics of patients in Training and Validation cohorts

From: A nomogram predicting overall survival in patients with non-metastatic pancreatic head adenocarcinoma after surgery: a population-based study

Characteristics

Training cohort (n = 4495)

Validation cohort (n = 1924)

p value

Age (year)

n (%)

n (%)

0.070

  < 40

38 (0.8%)

6 (0.3%)

 

 40–60

1010 (22.5%)

454 (23.6%)

 

 60–80

2984 (66.4%)

1280 (66.5%)

 

  ≥ 80

463 (10.3%)

184 (9.6%)

 

Gender

  

0.102

 Female

2226 (49.5%)

910 (47.3%)

 

 Male

2269 (50.5%)

1014 (52.7%)

 

Race

  

0.413

 White

3712 (82.6%)

1596 (83.0%)

 

 Black

411 (9.1%)

186 (9.6%)

 

 Others

372 (8.3%)

142 (7.4%)

 

8th T stage

  

0.100

 T1

739 (16.4%)

293 (15.2%)

 

 T2

2798 (62.2%)

1195 (62.1%)

 

 T3

786 (17.5%)

376 (19.6%)

 

 T4

172 (3.8%)

60 (3.1%)

 

8th N stage

  

0.931

 N0

1321 (29.4%)

561 (29.1%)

 

 N1

1823 (40.6%)

790 (41.1%)

 

 N2

1351 (30.0%)

573 (29.8%)

 

Grade

  

0.086

 Well

476 (10.6%)

222 (11.5%)

 

 Moderate

2355 (52.4%)

1005 (52.2%)

 

 Poor

1638 (36.4%)

676 (35.2%)

 

 Undifferentiated

26 (0.6%)

21 (1.1%)

 

LNR

  

0.590

 1

3086 (68.7%)

1334 (69.3%)

 

 2

1409 (31,3%)

590 (30.7%)

 

Tumor size (cm)

  

0.909

  ≤ 2.5

1547 (34.4%)

665 (34.6%)

 

  > 2.5

2948 (65.6%)

1259 (65.4%)

 

Radiotherapy

  

0.647

 No/unkown

3054 (67.9%)

1296 (67.4%)

 

 Yes

1441 (32.1%)

628 (32.6%)

 

Chemotherapy

  

0.999

 No/unkown

1133 (25.2%)

485 (25.2%)

 

 Yes

3362 (74.8%)

1439 (74.8%)

 

8th AJCC stage

  

0.749

 Stage I

1100 (24.5%)

460 (23.9%)

 

 Stage II

1931 (43.0%)

846 (44.0%)

 

 Stage III

1464 (32.5%)

618 (32.1%)

 

RLNs

17 [12–24]

17 [11.25–23]

0.409

PLNs

2 [0–4]

2 [0–4]

0.689

mOS (months)

16 [8–28]

16 [9–27]

0.539

  1. LNR lymph node ratio, RLNs retrieved lymph nodes, PLNs positive lymph nodes, mOS median overall survival